Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation
- 24 September 2013
- journal article
- case report
- Published by Wolters Kluwer Health in Neurology
- Vol. 81 (13) , 1176-1178
Abstract
We previously reported clinical improvement, increase in putamen [(18)F]-dopa uptake on PET imaging, and neuropathologic evidence of sprouting of dopaminergic fibers following chronic intraputaminal delivery of glial cell line-derived neurotrophic factor (GDNF) in idiopathic Parkinson disease (PD).(1-3) We now provide clinical and PET evidence of persistent efficacy lasting for at least 3 years following cessation of GDNF infusion in a patient with PD. This is a single-case observational study, providing Class IV evidence.Keywords
This publication has 6 references indexed in Scilit:
- Unilateral intraputamenal glial cell line–derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawalJournal of Neurosurgery, 2007
- Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson diseaseAnnals of Neurology, 2006
- Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brainNature Medicine, 2005
- Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome studyAnnals of Neurology, 2005
- Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson diseaseNature Medicine, 2003
- Core assessment program for intracerebral transplantations (CAPIT)Movement Disorders, 1992